Viral breakthrough during lamivudine therapy for chronic hepatitis B

Intervirology

Volumn 46, Issue 6, 2003, Pages 344-349

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiviral agents; Hepatitis B e antigen; Hepatitis B virus; Lamivudine; Resistant mutants

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; INTERFERON; LAMIVUDINE; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ACCURACY; ASSAY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG POTENCY; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PRACTICE GUIDELINES;

HEPATITIS B VIRUS;

EID: 0347362543     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074990     Document Type: Conference Paper

References (25)

1. Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2001;120:1828-1853.
2. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001;34:1225-1241.
3. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527.
4. Kao JH: Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
5. Manesis EK, Papatheodoridis GV, Hadziyannis SJ: Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002;122:2092-2093.
6. Liaw YF, Leung N, Guan R, Lau GK, Merican I: Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003;18:239-245.
7. Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ: Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. J Clin Microbiol 2000;38:3205-3208.
8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
10. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896.
11. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-568.
12. Guan R, Lai CL, Leung NWY, Lim SG, Lee CM, Ng KY, Chang TT, Nicholls GJ, Dent JC: Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstract). J Gastroenterol Hepatol 2001;S16:A60.
13. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
14. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
15. Schiff ER, Cianciara J, Willems B, Karayalcin S, Brown NA, Marr CL, Gray F, et al: Durability of HBeAg responses to lamivudine and interferon in the early post-treatment period in adults with chronic hepatitis B (abstract). Hepatology 2000;32:337A.
16. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
17. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD: Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-3347.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
19. Leung N: Treatment of chronic hepatitis B: Case selection and duration of therapy. J Gastroenterol Hepatol 2002;17:409-414.
20. Liaw YF: Therapy of chronic hepatitis B: Current challenges and opportunities. J Viral Hepat 2002;9:393-399.
21. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
22. Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S: Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
23. Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Namini H, Xiang S, James C, Ho V, Fry J, Brosgart C: Sustained antiviral response and lack of viral resistance in long term adefovir dipivoxil (ADV) therapy in chronic HBV infection (abstract). J Hepatol 2002;36:S110.
24. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F: Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-1740.
25. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838.